<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3222044</article-id><article-id pub-id-type="publisher-id">cc9416</article-id><article-id pub-id-type="doi">10.1186/cc9416</article-id><article-categories><subj-group subj-group-type="heading"><subject>Errata</subject></subj-group></article-categories><title-group><article-title>Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients
with sepsis: an <italic>a priori</italic>-designed analysis of the MENDS randomized
controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Pandharipande</surname><given-names>Pratik P</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Sanders</surname><given-names>Robert D</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>robert.sanders@ic.ac.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Girard</surname><given-names>Timothy D</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>McGrane</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Thompson</surname><given-names>Jennifer L</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Shintani</surname><given-names>Ayumi K</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Herr</surname><given-names>Daniel L</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Maze</surname><given-names>Mervyn</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Ely</surname><given-names>E Wesley</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref></contrib><on-behalf-of>the MENDS investigators<xref ref-type="corresp" rid="d33e91"/></on-behalf-of></contrib-group><aff id="I1"><label>1</label>Anesthesiology Service, VA TN Valley Health Care System, 1310 24th Avenue
South, Nashville, TN 37212-2637, USA</aff><aff id="I2"><label>2</label>Department of Anesthesiology, Division of Critical Care, Vanderbilt
University School of Medicine; 324 MAB, Nashville, TN 37212-1120, USA</aff><aff id="I3"><label>3</label>Department of Leucocyte Biology &#x00026; Magill Department of Anaesthetics,
Intensive Care and Pain Medicine, Imperial College London, Chelsea &#x00026;
Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK</aff><aff id="I4"><label>4</label>Department of Medicine, Division of Allergy, Pulmonary, and Critical Care
Medicine, Vanderbilt University School of Medicine; T-1218 MCN, Nashville,
TN 37232-2650, USA</aff><aff id="I5"><label>5</label>Center for Health Services Research, Vanderbilt University School of
Medicine; 6th Floor MCE, Suite 6100, Nashville, TN 37232-8300, USA</aff><aff id="I6"><label>6</label>Veterans Affairs Tennessee Valley Geriatric Research, Education, and Clinical
Center; 1310 24th Avenue South, Nashville, TN 37212-2637, USA</aff><aff id="I7"><label>7</label>Department of Biostatistics, Vanderbilt University School of Medicine; S-2323
MCN, Nashville, TN 37232-2158, USA</aff><aff id="I8"><label>8</label>Department of Surgery and Surgical Critical Care, Washington Hospital Center;
110 Irving St NW, Room 4B42, Washington, DC 20010, USA</aff><aff id="I9"><label>9</label>Department of Anesthesiology and Perioperative Care, University of California
San Francisco; 521 Parnassus Avenue, C455, San Francisco, CA 94143-0648,
USA</aff><author-notes><corresp id="d33e91">the MENDS investigators</corresp></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>1</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>1</month><year>2012</year></pub-date><volume>15</volume><issue>1</issue><fpage>402</fpage><lpage>402</lpage><permissions><copyright-statement>Copyright &#x000a9; 2011 BioMed Central Ltd</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/15/1/402"/><related-article related-article-type="corrected-article" id="d33e6" vol="14" page="R38" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="20233428" ext-link-type="pubmed"/></article-meta></front><body><sec><title/><p>After publication of our article [<xref ref-type="bibr" rid="B1">1</xref>], we noted
typographical errors in our tables and in the labelling of Figure 3 (Figure <xref ref-type="fig" rid="F1">1</xref>). There have been no changes to the results or their
interpretation.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Kaplan-Meier curve showing probability of survival during the first 28
days according to treatment group, among patients with sepsis</bold>.
Dexmedetomidine decreased the probability of dying within 28 days by 70%;
this beneficial effect was not seen in patients who were not septic (<italic>P
</italic>value for interaction = 0.11 implying an interaction between sepsis and
the treatment groups).</p></caption><graphic xlink:href="cc9416-1"/></fig><p>In Table <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>
the number of dexmedetomidine patients without sepsis should read 21 instead of the
published 20. The numbers in the corresponding text are correct. The corrected
tables can be found overleaf.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of patients with and without sepsis*</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="2">Patients with sepsis</th><th align="center" colspan="2">Patients without sepsis</th></tr><tr><th/><th colspan="2"><hr/></th><th colspan="2"><hr/></th></tr><tr><th align="left">Variable</th><th align="center">DEX (n = 31)</th><th align="center">LZ (n = 32)</th><th align="center">DEX (n = 21)</th><th align="center">LZ (n = 19)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="center">60 (46, 65)</td><td align="center">58 (44, 66)</td><td align="center">61 (50, 68)</td><td align="center">60 (52, 67)</td></tr><tr><td align="left">Males</td><td align="center">58%</td><td align="center">41%</td><td align="center">57%</td><td align="center">53%</td></tr><tr><td align="left">APACHE II</td><td align="center">30 (26, 34)</td><td align="center">29 (24, 32)</td><td align="center">27 (20, 31)</td><td align="center">25 (20, 30)</td></tr><tr><td align="left">SOFA score</td><td align="center">10 (9,13)</td><td align="center">9 (8, 12)</td><td align="center">9 (8, 12)</td><td align="center">8 (7, 9)</td></tr><tr><td align="left">IQCODE at enrollment</td><td align="center">3 (3, 3)</td><td align="center">3 (3, 3)</td><td align="center">3 (3, 3)</td><td align="center">3 (3, 3)</td></tr><tr><td align="left">Medical ICU</td><td align="center">77%</td><td align="center">81%</td><td align="center">62%</td><td align="center">47%</td></tr><tr><td align="left">Surgical ICU</td><td align="center">23%</td><td align="center">19%</td><td align="center">38%</td><td align="center">53%</td></tr><tr><td align="left">Pre-enrollment lorazepam (mg)</td><td align="center">1.5 (0, 5)</td><td align="center">0 (0, 4)</td><td align="center">0 (0, 4)</td><td align="center">0 (0, 2)</td></tr><tr><td align="left">Enrollment RASS</td><td align="center">-3 (-4, -2)</td><td align="center">-4 (-4, -3)</td><td align="center">-3 (-4, 0)</td><td align="center">-3 (-4, -1)</td></tr><tr><td align="left"><bold>SIRS criteria</bold></td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Temperature (Fahrenheit)</td><td align="center">37.5 (37, 38.3)</td><td align="center">38 (37.2, 38.6)</td><td align="center">36.7 (35.8, 37.8)</td><td align="center">37.2 (36.2, 38.3)</td></tr><tr><td align="left">&#x02003;White blood count (10<sup>3</sup>/&#x003bc;L)</td><td align="center">12.5 (6.6, 21.7)</td><td align="center">12.5 (7.7, 18.8)</td><td align="center">14.6 (8.9,17.9)</td><td align="center">10 (7.5,14)</td></tr><tr><td align="left">&#x02003;Systolic BP (mm Hg)</td><td align="center">88 (78, 100)</td><td align="center">83 (79, 100)</td><td align="center">92 (90, 100)</td><td align="center">90 (80,110)</td></tr><tr><td align="left">&#x02003;Heart rate (per minute)</td><td align="center">113 (100, 134)</td><td align="center">119 (96, 130)</td><td align="center">80 (65,123)</td><td align="center">107 (99, 126)</td></tr><tr><td align="left">&#x02003;Respiratory rate</td><td align="center">26 (20, 33)</td><td align="center">33 (27, 39)</td><td align="center">20 (15, 24)</td><td align="center">24 (20,28)</td></tr><tr><td align="left"><bold>Organ dysfunction at enrollment</bold></td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;PaO<sub>2</sub>/FiO<sub>2 </sub>ratio</td><td align="center">128 (105, 209)</td><td align="center">126 (94, 198)</td><td align="center">127 (72, 211)</td><td align="center">145 (81, 223)</td></tr><tr><td align="left">&#x02003;Creatinine (mg/dL)</td><td align="center">1.7 (0.8, 2.9)</td><td align="center">1.0 (0.8, 1.8)</td><td align="center">1.2 (1.0, 1.7)</td><td align="center">0.9 (0.8, 1.4)</td></tr><tr><td align="left">&#x02003;Vasopressors</td><td align="center">32%</td><td align="center">56%</td><td align="center">19%</td><td align="center">5%</td></tr><tr><td align="left">&#x02003;Bilirubin (mg/dL)</td><td align="center">0.5 (0.4, 0.8)</td><td align="center">0.9 (0.4, 1.8)</td><td align="center">0.6 (0.5, 1.6)</td><td align="center">0.6 (0.4, 1.1)</td></tr><tr><td align="left">&#x02003;Platelets (10<sup>3</sup>/&#x003bc;L)</td><td align="center">176 (61, 304)</td><td align="center">183 (107, 266)</td><td align="center">186 (101,242)</td><td align="center">145 (114, 242)</td></tr></tbody></table><table-wrap-foot><p>Median (interquartile range) unless otherwise noted</p><p>*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; APACHE II, Acute
Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure
Assessment; IQCODE, Informant Questionnaire on Cognitive Decline in the
Elderly; ICU, intensive care unit; SIRS, Systemic Inflammatory Response
Syndrome; BP, Blood pressure.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Outcomes of patients with and without sepsis*</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="3">Patients with sepsis</th><th align="center" colspan="3">Patients without sepsis</th></tr><tr><th/><th colspan="3"><hr/></th><th colspan="3"><hr/></th></tr><tr><th align="left">Outcome variable</th><th align="center">DEX (n = 31)</th><th align="center">LZ (n = 32)</th><th align="center">Adjusted<break/><italic>P </italic>value**</th><th align="center">DEX (n = 21)</th><th align="center">LZ (n = 19)</th><th align="center">Adjusted<break/><italic>P </italic>value**</th></tr></thead><tbody><tr><td align="left"><bold>Duration of Brain Organ Dysfunction</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Delirium/coma-free days**</td><td align="center">6.1 (4.3)</td><td align="center">2.9 (3.2)</td><td align="center">0.005</td><td align="center">6 (4.7)</td><td align="center">5.5 (3.6)</td><td align="center">0.97</td></tr><tr><td align="left">&#x02003;Delirium-free days<sup>&#x02020;</sup></td><td align="center">8.1 (3.1)</td><td align="center">6.7 (2.9)</td><td align="center">0.06</td><td align="center">8.1 (3.5)</td><td align="center">7.9 (2.8)</td><td align="center">0.80</td></tr><tr><td align="left">&#x02003;Coma-free days<sup>&#x000a7;</sup></td><td align="center">9.4 (2.9)</td><td align="center">5.9 (4.2)</td><td align="center">&#x0003c; 0.001</td><td align="center">8.9 (4)</td><td align="center">8.8 (2.6)</td><td align="center">1</td></tr><tr><td align="left"><bold>Other clinical outcomes</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;MV-free days<sup>&#x02021;</sup></td><td align="center">15.2 (10.6)</td><td align="center">10.1 (10.3)</td><td align="center">0.03</td><td align="center">12.8 (11.5)</td><td align="center">17.2 (10)</td><td align="center">0.15</td></tr><tr><td align="left">&#x02003;ICU days</td><td align="center">13.4 (15.1)</td><td align="center">12.2 (9.8)</td><td align="center">0.81</td><td align="center">14.9 (16.5)</td><td align="center">10.4 (8.9)</td><td align="center">0.28</td></tr><tr><td align="left">&#x02003;28-day mortality</td><td align="center">16%</td><td align="center">41%</td><td align="center">0.03</td><td align="center">19%</td><td align="center">5%</td><td align="center">0.21</td></tr></tbody></table><table-wrap-foot><p>Mean (standard deviation) unless otherwise noted</p><p>Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; ICU, intensive care unit;
MV, mechanical ventilation</p><p>*Adjusted <italic>P </italic>value obtained from the bootstrap multiple linear
regression that calculated a difference in mean for each outcome between the
two treatment groups, adjusting for age, severity of illness, use of
drotrecogin alfa (activated) within 48 hours of enrollment, sepsis,
treatment group, and a treatment group by sepsis interaction.</p><p>**Indicates the number of days alive without delirium or coma from study day
1 to 12.</p><p><sup>&#x02020;</sup>Indicates the number of days alive without delirium from
study day 1 to 12.</p><p><sup>&#x000a7;</sup>Indicates the number of days alive without coma from study
day 1 to 12.</p><p><sup>&#x02021;</sup>Indicates the number of days alive breathing without
assistance of the ventilator from study day 1 to 28.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Hemodynamic parameters in patients with and without sepsis*</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="3">Patients with sepsis</th><th align="center" colspan="3">Patients without sepsis</th></tr><tr><th/><th colspan="3"><hr/></th><th colspan="3"><hr/></th></tr><tr><th align="left">Hemodynamic variable**</th><th align="center">DEX (n = 31)</th><th align="center">LZ (n = 32)</th><th align="center">P value</th><th align="center">DEX (n = 21)</th><th align="center">LZ (n = 19)</th><th align="center">P value</th></tr></thead><tbody><tr><td align="left">Number of days on vasoactive drugs</td><td align="center">1 (1)</td><td align="center">2 (2)</td><td align="center">0.08</td><td align="center">1.5 (2.2)</td><td align="center">0.3 (0.9)</td><td align="center">0.08</td></tr><tr><td align="left">Average daily number of vasoactive drugs</td><td align="center">1.1 (0.2)</td><td align="center">1.6 (0.5)</td><td align="center">0.004</td><td align="center">1.6 (0.9)</td><td align="center">1 (0)</td><td align="center">0.2</td></tr><tr><td align="left">Ever vasoactive drugs increased</td><td align="center">26%</td><td align="center">47%</td><td align="center">0.08</td><td align="center">33%</td><td align="center">16%</td><td align="center">0.2</td></tr><tr><td align="left">Sinus bradycardia (&#x0003c; 60 beats/min)</td><td align="center">13%</td><td align="center">6%</td><td align="center">0.4</td><td align="center">24%</td><td align="center">0%</td><td align="center">0.02</td></tr><tr><td align="left">Sinus tachycardia (&#x0003e; 100 beats/min)</td><td align="center">81%</td><td align="center">84%</td><td align="center">0.7</td><td align="center">52%</td><td align="center">53%</td><td align="center">1</td></tr></tbody></table><table-wrap-foot><p>Mean (standard deviation) unless otherwise noted</p><p>*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam</p><p>** Measured during 120-hour study drug protocol, except for sinus bradycardia
&#x00026; sinus tachycardia, which are measured during entire study.</p></table-wrap-foot></table-wrap><p>In Figure 3 (Figure <xref ref-type="fig" rid="F1">1</xref>) in the "Patients at risk" table below
the Kaplan-Meier curve, the dexmedetomidine and lorazepam labels are incorrect. The
top row should be labeled lorazepam and the bottom row should be labeled
dexmedetomidine. The corrected figure can be found overleaf.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Pandharipande</surname><given-names>PP</given-names></name><name><surname>Sanders</surname><given-names>RD</given-names></name><name><surname>Girard</surname><given-names>TD</given-names></name><name><surname>McGrane</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Shintani</surname><given-names>AK</given-names></name><name><surname>Herr</surname><given-names>DL</given-names></name><name><surname>Maze</surname><given-names>M</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><collab>for the MENDS investigators</collab><article-title>Effect of dexmedetomidine versus lorazepam on outcome in patients with
sepsis: an <italic>a priori</italic>-designed analysis of the MENDS randomized
controlled trial</article-title><source>Crit Care</source><year>2010</year><volume>15</volume><fpage>R38</fpage><pub-id pub-id-type="doi">10.1186/cc8916</pub-id><pub-id pub-id-type="pmid">20233428</pub-id></mixed-citation></ref></ref-list></back></article>